Haije W G, Meerwaldt J H, Talerman A, Kuipers T j, Baggerman L, Teeuw A H, van der Pompe W B, van Driel J
Int J Cancer. 1979 Sep 15;24(3):288-93. doi: 10.1002/ijc.2910240304.
Using a sensitive enzyme immunoassay, carcinoplacental alkaline phosphatase (CPAP) was determined in sera of 1266 patients with gyneocological cancers. All these patients were referred after initial surgical treatment elsewhere. There were 95 patients with evidence of disease at the time of the study and 1171 without evidence of disease. Of the 95 patients with active disease, 47 were treated for ovarian carcinoma, 36 for carcinoma of the cervix and 12 for endometrial carcinoma. Raised levels of CPAP were seen in 40% of patients with ovarian carcinoma, in 22% with carcinoma of the cervix and in 41% in the small group with endometrial carcinoma. In patients without evidence of disease, raised levels of CPAP were seen in 12% of patients with carcinoma of the cervix, in 6% of endometrial carcinoma and only in 2% of patients with carcinoma of the ovary. Therefore it was considered that in the latter group CPAP studies would prove of some value. In the group of patients with carcinoma of the ovary and evidence of disease, raised levels of CPAP were seen almost exclusively in patients with epithelial tumors. It is considered that CPAP may be of value as a tumor marker in this group of patients. When compared with CEA, CPAP tends to give fewer false positives and correlates better with the presence of disease.
采用灵敏的酶免疫测定法，对1266例妇科癌症患者的血清进行了癌胎盘碱性磷酸酶（CPAP）检测。所有这些患者均在其他地方接受初始手术治疗后前来就诊。研究时，有95例患者有疾病证据，1171例无疾病证据。在95例患有活动性疾病的患者中，47例接受卵巢癌治疗，36例接受宫颈癌治疗，12例接受子宫内膜癌治疗。40%的卵巢癌患者、22%的宫颈癌患者以及41%的小样本子宫内膜癌患者CPAP水平升高。在无疾病证据的患者中，12%的宫颈癌患者、6%的子宫内膜癌患者以及仅2%的卵巢癌患者CPAP水平升高。因此，认为在后者组中CPAP研究将证明有一定价值。在有疾病证据的卵巢癌患者组中，CPAP水平升高几乎仅见于上皮性肿瘤患者。认为CPAP在该组患者中可能作为肿瘤标志物有价值。与癌胚抗原（CEA）相比，CPAP往往产生较少的假阳性，且与疾病存在的相关性更好。
